SCHEMBL26045754

SCHEMBL26045754

COC(=O)c1cc(Br)cc(C(F)F)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.40
NR4A2 P43354 1/20 0.37
GAA P10253 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HSD17B10 Q99714 2/20 0.36
SLC6A3 Q01959 1/20 0.36
SOS1 Q07889 1/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
PDK2 Q15119 1/20 0.34
PDK4 Q16654 1/20 0.34
OPRK1 P41145 1/20 0.34
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366609 1.00 NOTUM (0.40) NOTUMNR4A2GAAALDH1A1HSD17B10
SCHEMBL21932880 0.82 SLC6A4 (0.37) GAAALDH1A1HSD17B10SLC6A3SOS1
SCHEMBL19136407 0.82 NR4A2 (0.48) NR4A2GAAALDH1A1HSD17B10SLC6A3
SCHEMBL27002383 0.81 GABRA1 (0.34) ALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL29915017 0.81 GABRA1 (0.34) ALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL29363398 0.80 NOTUM (0.37) NOTUMNR4A2GAAALDH1A1HSD17B10
SCHEMBL22821220 0.80 NOTUM (0.37) NOTUMNR4A2GAAALDH1A1HSD17B10
SCHEMBL29841607 0.79 TPMT (0.36) GAAALDH1A1HSD17B10SLC6A3MAPT
SCHEMBL21198962 0.78 NOTUM (0.42) NOTUMNR4A2GAAALDH1A1HSD17B10
SCHEMBL29570702 0.78 NOTUM (0.42) NOTUMNR4A2GAAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS GENENTECH, INC. (US) 2025-07-17 US disclosed
EP-4288429-A1 LACTAMS AS CBL-B INHIBITORS Genentech, Inc. (US) 2023-12-13 EP disclosed
CN-116888112-A Lactams as CBL-B inhibitors 基因泰克公司 2023-10-13 CN disclosed
EP-3986566-B1 NEW EGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2023-08-30 EP disclosed
EP-3986566-B1 NEW EGFR INHIBITORS HOFFMANN LA ROCHE (CH) 2023-08-30 EP disclosed
US-20230079990-A1 LACTAMS AS CBL-B INHIBITORS GENENTECH, INC. (US) 2023-03-16 US disclosed
WO-2022169997-A1 LACTAMS AS CBL-B INHIBITORS GENENTECH, INC. (US) 2022-08-11 WO disclosed
EP-3986566-A1 NEW EGFR INHIBITORS F. Hoffmann-La Roche AG (CH) 2022-04-27 EP disclosed
CN-113993591-A Novel EGFR inhibitors 豪夫迈·罗氏有限公司 2022-01-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230147-A1 LACTAMS AS CBL-B INHIBITORS CBLB, CBL, CBLC NOTUM 2606/4885NR4A2 3945/4885GAA 774/4885
US-20230079990-A1 LACTAMS AS CBL-B INHIBITORS CBLB, CBL, CBLC NOTUM 2606/4885NR4A2 3945/4885GAA 774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.